During the last session, Predictive Oncology Inc (NASDAQ:POAI)’s traded shares were 48.29 million, with the beta value of the company hitting 1.24. At the end of the trading day, the stock’s price was $1.48, reflecting an intraday gain of 16.54% or $0.21. The 52-week high for the POAI share is $3.76, that puts it down -154.05 from that peak though still a striking 62.84% gain since the share price plummeted to a 52-week low of $0.55. The company’s market capitalization is $9.87M, and the average intraday trading volume over the past 10 days was 5.53 million shares, and the average trade volume was 1.18 million shares over the past three months.
Predictive Oncology Inc (POAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. POAI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Predictive Oncology Inc (NASDAQ:POAI) trade information
Predictive Oncology Inc (POAI) registered a 16.54% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 16.54% in intraday trading to $1.48, hitting a weekly high. The stock’s 5-day price performance is 23.33%, and it has moved by 102.74% in 30 days. Based on these gigs, the overall price performance for the year is -49.83%. The short interest in Predictive Oncology Inc (NASDAQ:POAI) is 0.15 million shares and it means that shorts have 1.26 day(s) to cover.
Predictive Oncology Inc (POAI) estimates and forecasts
Statistics show that Predictive Oncology Inc has outperformed its competitors in share price, compared to the industry in which it operates. Predictive Oncology Inc (POAI) shares have gone up 38.32% during the last six months, with a year-to-date growth rate more than the industry average at 40.23% against 25.20.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 350k as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 1.5M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 53.33%. While earnings are projected to return 40.23% in 2025.
POAI Dividends
Predictive Oncology Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Predictive Oncology Inc (NASDAQ:POAI)’s Major holders
Predictive Oncology Inc insiders own 2.16% of total outstanding shares while institutional holders control 4.01%, with the float percentage being 4.10%. ADVISORNET FINANCIAL, INC is the largest shareholder of the company, while 17.0 institutions own stock in it. As of 2024-06-30, the company held over 95.0 shares (or 0.0023% of all shares), a total value of $99.0 in shares.
Also, the Mutual Funds coming in first place with the largest holdings of Predictive Oncology Inc (POAI) shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Extended Market Index Fund owns about 69.88 shares. This amounts to just over 1.05 percent of the company’s overall shares, with a $0.1 million market value. The same data shows that the other fund manager holds slightly less at 34.66, or about 0.52% of the stock, which is worth about $51304.0.
